Verily, an Alphabet company, has acquired SignalPath, a Raleigh NC-based portfolio company of Highlander Partners.

SignalPath was founded in 2014 with the financial support of Highlander Partners with a specific focus on building a software platform to improve the ease and efficiency of clinical trial execution at research sites. SignalPath offers software that seeks to optimize management of a health system’s clinical trials portfolio.

“At SignalPath, we’ve created a better research ecosystem – one that combines a network of premier, technology-enabled research sites with a best-in-class suite of clinical trial tools to address the pain points experienced by patients, sites and sponsors,” said Brad Hirsch, a senior advisor to Highlander Partners and co-founder and chief executive officer of SignalPath. “Combining these capabilities with Verily’s clinical studies platforms business accelerates our ability to scale these solutions and make them available to a larger group of sites as well as provide entirely new opportunities to our network. It is another step forward in accelerating clinical research and helping get treatments to market faster.”